Dr. Erica L. Mayer, MD MPH
Claim this profileDana-Farber Cancer Institute
Studies Breast Cancer
Studies BRCA2 Mutation
7 reported clinical trials
18 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
Stage III
Stage IV
2BRCA2 Mutation
HER2 negative
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Erica L. Mayer, MD MPH is currently running
Niraparib + Dostarlimab
for Breast Cancer
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
Recruiting1 award Phase 211 criteria
Enzalutamide + Mifepristone or Chemotherapy
for Breast Cancer
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Recruiting1 award Phase 218 criteria
More about Erica L. Mayer, MD MPH
Clinical Trial Related3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Erica L. Mayer, MD MPH has experience with
- Avelumab
- Palbociclib
- Exemestane
- Niraparib
- Dostarlimab
- Fulvestrant
Breakdown of trials Erica L. Mayer, MD MPH has run
Breast Cancer
BRCA2 Mutation
BRCA1 Mutation
PALB2 Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erica L. Mayer, MD MPH specialize in?
Erica L. Mayer, MD MPH focuses on Breast Cancer and BRCA2 Mutation. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are Stage III.
Is Erica L. Mayer, MD MPH currently recruiting for clinical trials?
Yes, Erica L. Mayer, MD MPH is currently recruiting for 5 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Erica L. Mayer, MD MPH has studied deeply?
Yes, Erica L. Mayer, MD MPH has studied treatments such as Avelumab, Palbociclib, Exemestane.
What is the best way to schedule an appointment with Erica L. Mayer, MD MPH?
Apply for one of the trials that Erica L. Mayer, MD MPH is conducting.
What is the office address of Erica L. Mayer, MD MPH?
The office of Erica L. Mayer, MD MPH is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.